(September 19, 2017, 11:19 AM EDT) -- CHICAGO — The Illinois federal judge overseeing the testosterone replacement therapy multidistrict litigation on Sept. 18 denied a motion by defendants AbbVie Inc. and Abbott Laboratories to certify for interlocutory appeal the court’s ruling denying summary judgment on failure-to-warn claims (In Re: Testosterone Replacement Therapy Products Liability Litigation, No. 14-01748, N.D. Ill.)....